Financial Counselors Inc. Has $5.24 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Financial Counselors Inc. boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 22.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,592 shares of the medical research company's stock after buying an additional 4,896 shares during the quarter. Financial Counselors Inc. owned approximately 0.05% of Charles River Laboratories International worth $5,238,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after buying an additional 57 shares during the last quarter. Wolff Wiese Magana LLC acquired a new position in Charles River Laboratories International in the third quarter valued at approximately $32,000. Assetmark Inc. boosted its stake in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after acquiring an additional 173 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its stake in Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock valued at $58,000 after acquiring an additional 193 shares during the period. Finally, Covestor Ltd boosted its stake in Charles River Laboratories International by 40.9% in the third quarter. Covestor Ltd now owns 327 shares of the medical research company's stock valued at $65,000 after acquiring an additional 95 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded down $0.36 during trading on Friday, hitting $199.23. The company had a trading volume of 287,756 shares, compared to its average volume of 621,025. The company has a market cap of $10.19 billion, a P/E ratio of 25.00, a PEG ratio of 5.15 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52 week low of $176.48 and a 52 week high of $275.00. The business's 50-day moving average is $194.45 and its 200 day moving average is $205.15. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period in the previous year, the business earned $2.72 EPS. The company's revenue was down 1.6% on a year-over-year basis. Equities research analysts predict that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its shares are undervalued.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares of the company's stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

CRL has been the subject of several analyst reports. Barclays reduced their price objective on Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating for the company in a research report on Thursday, August 8th. Evercore ISI upped their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research report on Thursday, November 7th. StockNews.com downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Robert W. Baird cut their target price on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a research report on Friday, September 20th. Finally, JPMorgan Chase & Co. downgraded Charles River Laboratories International from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $270.00 to $205.00 in a research report on Thursday, August 8th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $214.38.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).